Venlafaxine
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Venlafaxine
Venlafaxine: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Venlafaxine, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 8 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| anxiety | licence in another country |
| depression | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| anxiety disorder |
| endogenous depression |
| major depressive disorder |
| phobic disorder |
| social phobia |
| unipolar depression |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 14402B | Efexor-XR | Capsule (modified release) 150 mg (as hy | Valid |
Safety Considerations
Contraindication-related conditions (from the knowledge graph, not label text). The knowledge graph links venlafaxine to the following conditions as contraindications. These should be checked against the TGA-approved Product Information:
- Cardiovascular: hypertension, long QT syndrome, cardiovascular and heart disease, cerebrovascular disorder
- Hepatic and renal: liver failure, liver disease, cirrhosis, gallbladder disease, impaired renal function
- Neurological and psychiatric: epilepsy, bipolar disorder and major affective disorder, substance-related disorder and drug dependence, neuroleptic malignant syndrome
- Other: angle-closure glaucoma and ocular hypertension, blood coagulation disease, hypertriglyceridaemia, hyperthyroidism (including Graves disease), inappropriate ADH syndrome, interstitial lung disease
Drug Interactions. 100 interactions were identified. Major-level examples in the compiled data are bupropion, lorcaserin, diethylpropion, dolasetron, palonosetron and phentermine. Moderate-level examples include aspirin, morphine, epinephrine, clarithromycin, aprepitant and famotidine.
Literature-reported safety signals. Withdrawal and discontinuation syndrome, cardiovascular toxicity, hyponatraemia, mania, delirium, ecchymosis and bleeding events. Use in children and adolescents carries a suicidality warning.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications, as label text was not available.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.